Fibroid Special Interest Group (FSIG)

Home  | Mission Statement | Officers | Message from Chair Of Interest to Members | Membership Information

  If you'd like to become a member of the FSIG, tell us.

Purpose of the ASRM Fibroid SIG

The principal purposes of the ASRM FSIG shall be to stimulate, support, and promote education, research, and knowledge in the field of fibroid development, growth, pathophysiology, clinical manifestations, and treatment. 

Back to the Top

Officers

• Chair:  William H. Catherino, M.D., Ph.D.

• Chair-Elect:  Ayman Al-Hendy, M.D., Ph.D.

• Program Chair:  Gregory Christman, M.D.

• Information Chair:  Bradley Hurst, M.D.

• Past Chair:  Ashgar Afsari, M.D.

Back to the Top

Of Interest to Members

• Meet the new FSIG Member Services Coordinator, Susanna Scarbrough

• Fibroid SIG Bylaws

• ASRM publications which discuss Myomas and Uterine Fibroids

• Message from the Chair

• NIH News

• Featured articles

Back to the Top

Message From The Chair

With ever-increasing evidence of the impact of leiomyomas on both implantation and pregnancy maintenance, the interest in a Fibroid Special Interest Group (FSIG) has continued to grow, resulting in its official recognition by the American Society for Reproductive Medicine in 2008. The FSIG has been, and continues to be, quite productive. Research and understanding of uterine fibroids is increasing, and FSIG serves as a forum for collaboration, direction, support, and information dissemination. If you care for patients who suffer from uterine leiomyomas, we hope that you will consider using the FSIG as a resource, and potentially participating in the FSIG.

Upcoming Highlights at ASRM 2009 in Atlanta, GA!

1. Postgraduate Course: Contemporary Understanding and Treatment of Fibroids to Optimize Pregnancy Outcome

2. Roundtables: Why are uterine fibroids more common in African Americans?

We look forward to continued productivity and outreach, and welcome your ideas and participation.

Bill Catherino, Chair
Fibroid Special Interest Group

Back to the Top

NIH News

The Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) is sponsoring a Request for Proposals titled, “Leiomyomata Uteri: Basic Science, Translational and Clinical Research” (R01) (http://grants.nih.gov/grants/guide/pa-files/PAR-08-102.html). The purpose of this Funding Opportunity Announcement is to encourage new and experienced investigators to submit high quality research grant applications with the goal of transforming advances in our understanding of the molecular basis of leiomyomata uteri (uterine fibroids) into new therapeutic options for prevention, treatment, and cure of this common benign gynecologic disorder. This solicitation focuses on basic science, and translational and clinical research studies that are innovative in their approach to determine the complex molecular basis of this disorder and approaches to clinical applications that improve outcomes. The application due date is May 20, 2009.

Back to the Top

Featured Articles-2008 (bold denotes FSIG members)

• Agdi M, Tulandi T. Endoscopic management of uterine fibroids. Best Pract Res Clin Obstet Gynaecol. 2008 Aug;22(4):707-16.

• Behera MA, Feng L, Yonish B, Catherino W, Jung SH, Leppert P. Thrombospondin-1 and thrombospondin-2 mRNA and TSP-1 and TSP-2 protein expression in uterine fibroids and correlation to the genes COL1A1 and COL3A1 and to the collagen cross-link hydroxyproline. Reprod Sci. 2007 Dec;14(8 Suppl):63-76.

• Browne H, McCarthy-Keith D, Stegmann B, Spies J, Armstrong A. Ovarian response in women undergoing ovarian stimulation after myomectomy. Fertil Steril. 2008 Nov;90(5):2004.e19-21.

• Goodwin SC, Spies JB, Worthington-Kirsch R, Peterson E, Pron G, Li S, Myers ER; Fibroid Registry for Outcomes Data (FIBROID) Registry Steering Committee and Core Site Investigators. Uterine artery embolization for treatment of leiomyomata: long-term outcomes from the FIBROID Registry. Obstet Gynecol. 2008 Jan;111(1):22-33.

• Hassan MH, Eyzaguirre E, Arafa HM, Hamada FM, Salama SA, Al-Hendy A. Memy I: a novel murine model for uterine leiomyoma using adenovirus-enhanced human fibroid explants in severe combined immune deficiency mice. Am J Obstet Gynecol. 2008 Aug;199(2):156.e1-8.

• Hermon TL, Moore AB, Yu L, Kissling GE, Castora FJ, Dixon D. Estrogen receptor alpha (ERalpha) phospho-serine-118 is highly expressed in human uterine leiomyomas compared to matched myometrium. Virchows Arch. 2008 Dec;453(6):557-569.

• Hodge JC, Quade BJ, Rubin MA, Stewart EA, Dal Cin P, Morton CC. Molecular and cytogenetic characterization of plexiform leiomyomata provide further evidence for genetic heterogeneity underlying uterine fibroids. Am J Pathol. 2008 May;172(5):1403-10.

• Ishikawa H, Fencki V, Marsh EE, Yin P, Chen D, Cheng YH, Reisterd S, Lin Z, Bulun SE. CCAAT/enhancer binding protein beta regulates aromatase expression via multiple and novel cis-regulatory sequences in uterine leiomyoma. J Clin Endocrinol Metab. 2008 Mar;93(3):981-91.

• Malik M, Webb J, Catherino WH. Retinoic acid treatment of human leiomyoma cells transformed the cell phenotype to one strongly resembling myometrial cells. Clin Endocrinol (Oxf). 2008 Sep;69(3):462-70.

• Samuel A, Fennessy FM, Tempany CM, Stewart EA. Avoiding treatment of leiomyosarcomas: the role of magnetic resonance in focused ultrasound surgery. Fertil Steril. 2008 Sep;90(3):850.e9-12.

• Morikawa A, Ohara N, Xu Q, Nakabayashi K, DeManno DA, Chwalisz K, Yoshida S, Maruo T. Selective progesterone receptor modulator asoprisnil down-regulates collagen synthesis in cultured human uterine leiomyoma cells through up-regulating extracellular matrix metalloproteinase inducer. Hum Reprod. 2008 Apr;23(4):944-51.

• Pan Q, Luo X, Chegini N. Differential expression of microRNAs in myometrium and leiomyomas and regulation by ovarian steroids. J Cell Mol Med. 2008 Jan-Feb;12(1):227-40. 

• Rogers R, Norian J, Malik M, Christman G, Abu-Asab M, Chen F, Korecki C, Iatridis J, Catherino WH, Tuan RS, Dhillon N, Leppert P, Segars JH. Mechanical homeostasis is altered in uterine leiomyoma. Am J Obstet Gynecol. 2008 Apr;198(4):474.e1-11.

Back to the Top

Membership Information

 If you'd like to become a member of the FSIG, tell us.

If you would like more information regarding the FSIG, please contact: 

Back to the Top

By accessing and using the ASRM Web Site, you agree to be bound by 
the ASRM Web Site Terms and Conditions of Use.  

View the ASRM Non Discrimination Policy

Copyright 1996-2009 ASRM, All Rights Reserved
American Society for Reproductive Medicine

Listed on Infertility Resources
Developed and hosted by Internet Health Resources